

論文全著者名. 論題. 雑誌名. 発行年; 巻:始頁-終頁	著者名
Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. PLoS One. 2018 Aug 28;13(8):e0203070. doi: 10.1371/journal.pone.0203070. eCollection 2018.	Yano Y, Kurebe H, Eda Hiro R, Hosono Y, Nakatsubo S, Nishida K, Sawa N, Ishijima M, Uenami T, Kanazu M, Akazawa Y, Yamaguchi T, Mori M
Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series. Thorac Cancer. 2018 Dec;9(12):1782-1787. doi: 10.1111/1759-7714.12894. Epub 2018 Oct 17.	Kanazu M, Eda Hiro R, Krebe H, Nishida K, Ishijima M, Uenami T, Akazawa Y, Yano Y, Yamaguchi T, Mori M
Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression. Ann Transl Med. 2018 Nov;6(22):444. doi: 10.21037/atm.2018.10.24.	Uenami T, Ishijima M, Kanazu M, Kurebe H, Eda Hiro R, Nishida K, Akazawa Y, Yano Y, Yamaguchi T, Mori M
Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer. Cancer Chemother Pharmacol. 2018 Jul;82(1):111-117. doi: 10.1007/s00280-018-3598-4. Epub 2018 May 4.	Koba T, Minami S, Nishijima-Futami Y, Masuhiro K, Kimura H, Futami S, Yaga M, <u>Mori M</u> , <u>Kagawa H</u> , <u>Uenami T</u> , Kohmo S, Otsuka T, Yamamoto S, Komuta K, Kijima T
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.	Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, <u>Mori M</u> , Aoe K, Morita S, Negoro S
HANSHIN Oncology Group. Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study). Cancer. 2018 Sep 7. doi: 10.1002/cncr.31678. [Epub ahead of print]	Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, <u>Kimura H</u> , <u>Yano Y</u> , Tamura D, Morita S, Negoro S
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer. 2018 Oct 3;18(1):946. doi: 10.1186/s12885-018-4819-2.	Tachihara M, Negoro S, Inoue T, Tamiya M, <u>Akazawa Y</u> , <u>Uenami T</u> , Urata Y, Hattori Y, Hata A, Katakami N, Yokota S

<p>Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018 Oct 4;3(19). pii: 59125. doi: 10.1172/jci.insight.59125. [Epub ahead of print]</p>	<p>Osa A, <u>Uenami I</u>, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, Hirata H, <u>Yano Y</u>, <u>Yokota S</u>, Kinehara Y, Naito Y, Otsuka T, <u>Kanazu M</u>, Kuroyama M, Hamaguchi M, Koba T, Futami Y, <u>Ishijima M</u>, Suga Y, <u>Akazawa Y</u>, Machiyama H, Iwahori K, Takamatsu H, Nagatomo I, Takeda Y, Kida H, Akbay EA, Hammerman PS, Wong KK, Dranoff G, <u>Mori M</u>, Kijima T, Kumanogoh A</p>
<p>HANSHIN Oncology Group. Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients? Oncotarget. 2018 Oct 5;9(78):34765-34771. doi: 10.18632/oncotarget.26192. eCollection 2018 Oct 5.</p>	<p>Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, <u>Kimura H</u>, <u>Yano Y</u>, Tamura D, Morita S, Negoro S</p>
<p>Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13). Oncol Lett. 2019 Jan;17(1):1320-1326.</p>	<p>Kunikane H, Yokota I, Katakami N, Takeda K, Takayama K, Sawa T, Saito H, Harada M, <u>Yokota S</u>, Ando K, Saito Y, Ohashi Y, Eguchi K.</p>
<p>A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102. Intern Med. 2019 Feb 1. doi: 10.2169/internalmedicine.1172-18. [Epub ahead of print]</p>	<p>Yokoi T, Minami S, Shiroyama T, Koba T, Torii Y, Sugimoto H, Niki M, <u>Mori M</u>, Morimura O, Hirashima T, Komuta K, Kijima T</p>
<p>Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer. In Vivo. 2019 Mar-Apr;33(2):477-482. doi: 10.21873/in vivo.11498.</p>	<p>Kitagawa C, <u>Mori M</u>, Ichiki M, Sukoh N, Kada A, Saito AM, Ichinose Y</p>
<p>メディカル・トピックス「肺がん内科治療で免疫治療薬が主役になるかも？」. 豊中市医師会月報 2018年7</p>	<p>森 雅秀</p>